- Home
- TEI vs NGNE Comparison
TEI vs NGNE Comparison
Compare TEI & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEI
- NGNE
- Stock Information
- Founded
- TEI 1993
- NGNE 2003
- Country
- TEI United States
- NGNE United States
- Employees
- TEI N/A
- NGNE N/A
- Industry
- TEI Finance Companies
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- TEI Finance
- NGNE Health Care
- Exchange
- TEI Nasdaq
- NGNE Nasdaq
- Market Cap
- TEI 282.9M
- NGNE 325.3M
- IPO Year
- TEI N/A
- NGNE N/A
- Fundamental
- Price
- TEI $6.07
- NGNE $20.51
- Analyst Decision
- TEI
- NGNE Strong Buy
- Analyst Count
- TEI 0
- NGNE 7
- Target Price
- TEI N/A
- NGNE $41.86
- AVG Volume (30 Days)
- TEI 142.4K
- NGNE 114.6K
- Earning Date
- TEI 01-01-0001
- NGNE 08-11-2025
- Dividend Yield
- TEI 10.51%
- NGNE N/A
- EPS Growth
- TEI N/A
- NGNE N/A
- EPS
- TEI N/A
- NGNE N/A
- Revenue
- TEI N/A
- NGNE N/A
- Revenue This Year
- TEI N/A
- NGNE N/A
- Revenue Next Year
- TEI N/A
- NGNE N/A
- P/E Ratio
- TEI N/A
- NGNE N/A
- Revenue Growth
- TEI N/A
- NGNE N/A
- 52 Week Low
- TEI $4.35
- NGNE $6.88
- 52 Week High
- TEI $5.39
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- TEI 58.45
- NGNE 47.72
- Support Level
- TEI $6.05
- NGNE $18.94
- Resistance Level
- TEI $6.13
- NGNE $21.59
- Average True Range (ATR)
- TEI 0.05
- NGNE 1.40
- MACD
- TEI 0.00
- NGNE -0.26
- Stochastic Oscillator
- TEI 75.00
- NGNE 32.30
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.